The equilibrium and kinetic drug binding properties of the mouse P-gp1a and P-gp1b P-glycoproteins are similar. by Taylor, J, Ferry, DR, Higgins, C, Callaghan, R

Pre-clinical and clinical study of QC12, a water-soluble, pro-drug of quercetin by Mulholland, PJ, Ferry, DR, Anderson, D, Hussain, SA, Young, AM, Cook, JE, Hodgkin, E, Seymour, LW, Kerr, DJ

Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. by Seymour, L, Ferry, DR, Anderson, D, Hesslewood, S, Julyan, P, Poyner, R, Doran, J, Young, A, Burtles, S, Kerr, D

CAPECITABINE (CAPE) +/- BEVACIZUMAB (BEV) IN THE ADJUVANT TREATMENT OF COLORECTAL CANCER (CRC) FIRST AND FINAL TOXICITY RESULTS FROM THE INTERNATIONAL PHASE III QUASAR2 TRIAL by Midgley, R, Love, S, Potter, V, Segelov, E, Ferry, DR, Weaver, A, Scudder, C, Julier, P, Grumett, S, Kerr, D

FOxTROT: Randomized phase II study of neoadjuvant chemotherapy with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer by Gray, R, Morton, D, Brown, G, Ferry, DR, Magill, L, Quirke, P, Seymour, M, Warren, B, Grp, F

FOxTROT: Randomized phase II study of neoadjuvant chemotherapy (CT) with or without an anti-EGFR monoclonal antibody for locally advanced, operable colon cancer: Planned interim re... by Morton, D, Magill, L, Handley, K, Brown, G, Ferry, DR, Gray, Z, Quirke, P, Seymour, M, Warren, B, Gray, R, Grp, F

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. by Seymour, M, Maughan, T, Ledermann, J, Topham, C, James, R, Gwyther, S, Smith, D, Shepherd, S, Maraveyas, A, Ferry, DR, Meade, A, Thompson, L, Griffiths, G, Parmar, M, Stephens, R

Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. by Seymour, L, Ferry, DR, Kerr, D, Rea, D, Whitlock, M, Poyner, R, Boivin, C, Hesslewood, S, Twelves, C, Blackie, R, Schatzlein, A, Jodrell, D, Bissett, D, Calvert, H, Lind, M, Robbins, A, Burtles, S, Duncan, R, Cassidy, J

Patient-reported outcomes from a phase HI multicenter, randomized, double-blind, placebo-controlled trial of gefitinib versus placebo in esophageal cancer progressing alter chemoth... by Dutton, S, Blazeby, J, Petty, R, Mansoor, W, Thompson, J, Harrison, M, Abbas, H, Dahle-Smith, A, Chatterjee, A, Falk, S, Garcia-Alonso, A, Fyfe, D, Hubner, R, Gamble, T, Peachey, L, Harvey, C, Julier, P, Jankowski, J, Midgley, R, Ferry, DR, Grp, C

Gefitinib and EGFR gene copy number aberrations in esophageal cancer by Petty, RD, Dahle-Smith, A, Stevenson, DAJ, Osborne, A, Massie, D, Clark, C, Murray, GI, Dutton, SJ, Roberts, C, Chong, IY, Mansoor, W, Thompson, J, Harrison, M, Chatterjee, A, Falk, SJ, Elyan, S, Garcia-Alonso, A, Fyfe, DW, Wadsley, J, Chau, I, Ferry, DR, Miedzybrodzka, Z